National Comprehensive Cancer Network (NCCN) Issues New Set of Guidelines For Biosimilar Use

Goodwin
Contact

Goodwin

This month, a working group within the Pharmacy Directors Forum of the National Comprehensive Cancer Network (NCCN) has reviewed and highlighted “some of the potential challenges regarding adopting biosimilars into clinical practice,” making “several recommendations for the safe and efficient use of biosimilar medications in the clinical setting.” The group listed medication errors, financial toxicity for patients, and economic challenges for institutions/providers as potential risks when using biosimilar products in the care of patients.

The NCCN guidelines conclude that “[o]rganizations need to be prepared to support biosimilar adoption from an operational and clinical standpoint before financial benefits can be achieved. The NCCN Pharmacy Directors Forum strongly advocates for constant vigilance, communication and collaboration between ancillary services (e.g. medical staff, revenue cycle, prior authorization, information technology) to ensure safe practices are maintained and biosimilars are successfully adopted.”

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.